Search results
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 1 day agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI- ...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
WKBN 27 Youngstown· 14 hours agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study. First-in-class PD-1/IL-2 bispecific ...
20 Counties with the Highest Cancer Rates in the US
Insider Monkey via Yahoo Finance· 2 hours agoIn this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 21 hours agoA Phase 3 study is already underway with the initial results expected later this decade. But at...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 13 hours agoThe NDA is supported by results from JUPITER-02, a randomized, double...
Benefit for Warner Cox May 11
Rome Sentinel· 4 days agoThere will be a benefit for Warner Cox from noon to 4 p.m. Saturday, May 11 at the Remsen VFW, located at 10526 Steuben St. Cox is battling stage 4 non-small</ ...
Tongue Cancer: Everything You Need to Know
Verywell Health via Yahoo News· 3 days agoTongue cancer, a type of oral cancer, often begins as a painful lump or sore on the side of the tongue that may bleed and resist healing. Here’s what to...
MD Anderson Research Highlights for April 24, 2024
Newswise· 1 day agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These adva
EU regulators approve BeiGene's tislelizumab for lung cancer (NASDAQ:BGNE)
Seeking Alpha· 2 days agoEU regulators have approved BeiGene’s (NASDAQ:BGNE) tislelizumab for the treatment of three types of...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 hours agoPhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation
